Research from QureTech Bio co-founders published in PNAS
October 3, 2025
QureTech Bio co-founders Christina Stallings and Fredrik Almqvist have recently published a study in the prestigious journal Proceedings of the National Academy of Sciences (PNAS). The article, titled “Metabolic rewiring of isoniazid sensitivity in Mycobacterium tuberculosis”, investigates how the metabolic pathways of the tuberculosis bacterium can be reprogrammed to restore its sensitivity to isoniazid—a key first-line antibiotic in TB treatment. QureTech Bio is developing new treatments targeting TB in collaboration with Fimbrion Therapeutics.
Read the full article here: